There were three distinct groups of chemokines: (1) common throughout all the severe COVID‐19 patients (CCL4, 11, 14, 16, 1719, 25, 27 28), (2) common but significantly increased in the patients with fatal outcome (CCL18, 3, 15, 20, 24, 5, CXCL1 and 11, CXL17), and (3) specific to the deceased patients (CXCL1, 5, 12, 13, 14, 16, 9, 6). This evidence concerns the gene CXCL1 and COVID-19.